Published in J Neurol Sci on February 01, 2010
Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology (2012) 3.79
AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol (2010) 3.28
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol (2013) 1.79
Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation (2010) 1.60
Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol (2014) 1.38
The history of neuromyelitis optica. J Neuroinflammation (2013) 1.25
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation (2016) 1.20
Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PLoS One (2013) 1.18
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation (2016) 1.01
B cells in MS and NMO: pathogenesis and therapy. Semin Immunopathol (2014) 1.01
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation (2016) 1.01
An optimized immunohistochemistry technique improves NMO-IgG detection: study comparison with cell-based assays. PLoS One (2013) 1.01
Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies. J Neurol (2013) 0.99
'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook. J Neuroinflammation (2015) 0.98
Aquaporin-4 antibody neuromyelitis optica following anti-NMDA receptor encephalitis. J Neurol (2013) 0.97
Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. Neurol Neuroimmunol Neuroinflamm (2016) 0.96
Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. PLoS One (2013) 0.94
Differential diagnoses to MS: experiences from an optic neuritis clinic. J Neurol (2013) 0.93
Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degeneration. Neurol Neuroimmunol Neuroinflamm (2015) 0.93
Low vitamin B12 levels and gastric parietal cell antibodies in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol (2012) 0.91
Autoimmune causes of encephalitis syndrome in Thailand: prospective study of 103 patients. BMC Neurol (2013) 0.85
Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. J Neuroinflammation (2014) 0.85
Evaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serology. PLoS One (2012) 0.85
On the contribution of Thomas Clifford Allbutt, F.R.S., to the early history of neuromyelitis optica. J Neurol (2012) 0.84
Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol (2014) 0.84
Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. J Neuroinflammation (2014) 0.83
The case of the Marquis de Causan (1804): an early account of visual loss associated with spinal cord inflammation. J Neurol (2012) 0.83
A longitudinal brain magnetic resonance imaging study of neuromyelitis optica spectrum disorder. PLoS One (2014) 0.82
Steroid-responsive hearing impairment in NMO-IgG/aquaporin-4-antibody-positive neuromyelitis optica. J Neurol (2012) 0.82
Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus. Rheumatol Int (2011) 0.81
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. J Neuroinflammation (2016) 0.80
Detection of autoantibodies against aquaporin-5 in the sera of patients with primary Sjögren's syndrome. Immunol Res (2016) 0.79
Olfactory dysfunction in patients with neuromyelitis optica. Mult Scler Int (2013) 0.79
Clinical usefulness of cell-based indirect immunofluorescence assay for the detection of aquaporin-4 antibodies in neuromyelitis optica spectrum disorder. Ann Lab Med (2012) 0.78
Homology between Klebsiella pneumoniae and human aquaporin-4: no evidence for cross-reactivity in neuromyelitis optica. A study on 114 patients. J Neurol (2010) 0.78
Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis. J Neuroinflammation (2015) 0.78
Aquaporin-4 antibodies are not related to HTLV-1 associated myelopathy. PLoS One (2012) 0.77
Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. BMC Neurol (2014) 0.76
Antibodies to aquaporin-4 in non-small cell lung cancer: a study on 50 patients. Neurol Sci (2010) 0.75
Detection of Autoantibodies against Aquaporin-1 in the Sera of Patients with Primary Sjögren's Syndrome. Immune Netw (2017) 0.75
Accuracy of the Fluorescence-Activated Cell Sorting Assay for the Aquaporin-4 Antibody (AQP4-Ab): Comparison with the Commercial AQP4-Ab Assay Kit. PLoS One (2016) 0.75
CD58 polymorphisms associated with the risk of neuromyelitis optica in a Korean population. BMC Neurol (2014) 0.75
Development of an Aquaporin-4 Orthogonal Array of Particle-Based ELISA for Neuromyelitis Optica Autoantibodies Detection. PLoS One (2015) 0.75
Occurrence of Asymptomatic Acute Neuromyelitis Optica Spectrum Disorder-Typical Brain Lesions during an Attack of Optic Neuritis or Myelitis. PLoS One (2016) 0.75
The Etiological Spectrum of Acute Sensory Myelitis. J Clin Neurol (2015) 0.75
Brain antibodies in the cortex and blood of people with schizophrenia and controls. Transl Psychiatry (2017) 0.75
STAT4 Polymorphisms are Associated with Neuromyelitis Optica Spectrum Disorders. Neuromolecular Med (2017) 0.75
Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS. Neurol Neuroimmunol Neuroinflamm (2017) 0.75
Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. J Neurol (2016) 0.75
Association of TNFSF4 Polymorphisms with Neuromyelitis Optica Spectrum Disorders in a Chinese Population. J Mol Neurosci (2017) 0.75
Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology (2001) 3.41
Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology (2010) 3.40
IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology (2012) 2.78
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology (2009) 2.58
Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology (2010) 2.36
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology (2004) 2.04
NMO-IgG in the diagnosis of neuromyelitis optica. Neurology (2007) 1.77
Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 gp41. Science (1996) 1.76
Thromboelastography for monitoring prolonged hypercoagulability after major abdominal surgery. Anesth Analg (2001) 1.75
CD4+CD28- costimulation-independent T cells in multiple sclerosis. J Clin Invest (2001) 1.74
[Trauma care systems in Germany, USA and Australia. An international comparison]. Unfallchirurg (2010) 1.53
Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci (2011) 1.49
Gentamicin coating of metallic implants reduces implant-related osteomyelitis in rats. Bone (2003) 1.48
Haemodilution with dextran 40 and hydroxyethyl starch and its effect on cerebral microcirculation. J Neurol (1989) 1.43
Postinfectious inflammatory disorders: subgroups based on prospective follow-up. Neurology (2005) 1.43
Enthesitis of the elbow in psoriatic arthritis. J Rheumatol (1997) 1.42
Predictors of long-term mortality and cardiac events in patients with known or suspected coronary artery disease who survive major non-cardiac surgery. Anaesthesia (2005) 1.42
[CT coronary angiography in patients with atrial fibrillation]. Rofo (2005) 1.42
[Requirements of trauma networks in Lower Saxony]. Unfallchirurg (2009) 1.39
Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol (2014) 1.38
Small animal bone healing models: standards, tips, and pitfalls results of a consensus meeting. Bone (2011) 1.24
Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain (2003) 1.22
Anti-endothelial serum antibodies in a patient with Susac's syndrome. J Neurol Sci (2009) 1.21
Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neurobiol Dis (2010) 1.17
Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler (2011) 1.16
Biodegradable poly(D,L-lactide) coating of implants for continuous release of growth factors. J Biomed Mater Res (2001) 1.15
Two cases of benign neuromyelitis optica in patients with celiac disease. J Neurol (2009) 1.14
A new model of implant-related osteomyelitis in rats. J Biomed Mater Res B Appl Biomater (2003) 1.13
Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature. Clin Neurol Neurosurg (2011) 1.10
GABA-B-receptor antibodies in paraneoplastic brainstem encephalitis. J Neuroimmunol (2013) 1.10
A novel enzyme-linked immunosorbent assay using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cytoplasmic antibody-associated vasculitis. Ann Rheum Dis (2008) 1.10
Distinct populations of human immunodeficiency virus type 1 in blood and cerebrospinal fluid. AIDS Res Hum Retroviruses (1992) 1.09
Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry (2008) 1.08
Neuromyelitis optica (Devic's syndrome) as first manifestation of systemic lupus erythematosus. Lupus (2006) 1.06
Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry (2001) 1.05
Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol (2005) 1.05
'Noteomielite' accompanied by acute amaurosis (1844). An early case of neuromyelitis optica. J Neurol Sci (2011) 1.03
Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity. J Neurol (2014) 1.02
Rodent animal models of delayed bone healing and non-union formation: a comprehensive review. Eur Cell Mater (2013) 1.02
Membrane association and RNA binding of recombinant hepatitis A virus protein 2C. Arch Virol (1998) 1.02
Testing for antibodies to human aquaporin-4 by ELISA: sensitivity, specificity, and direct comparison with immunohistochemistry. J Neurol Sci (2012) 1.02
Influence of age on the cell biological characteristics and the stimulation potential of male human tenocyte-like cells. Eur Cell Mater (2012) 1.02
Elevated plasma levels of S-100b protein in schizophrenic patients. Biol Psychiatry (1999) 1.01
Dendritic cells signal T cells in the absence of exogenous antigen. Nat Immunol (2001) 1.00
Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Mult Scler (2004) 1.00
Susac's syndrome: improvement with combined antiplatelet and calcium antagonist therapy. Stroke (1996) 0.98
Membrane permeability induced by hepatitis A virus proteins 2B and 2BC and proteolytic processing of HAV 2BC. Virology (1998) 0.98
[The influence of transportation mode on mortality in polytraumatized patients. An analysis based on the German Trauma Registry]. Unfallchirurg (2007) 0.98
Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry (2010) 0.96
IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis. J Immunol (2000) 0.96
Infusion of recombinant tissue plasminogen activator for treatment of basilar artery occlusion. Stroke (1990) 0.95
Systemic versus local application of gentamicin in prophylaxis of implant-related osteomyelitis in a rat model. Bone (2005) 0.95
An early case of neuromyelitis optica: on a forgotten report by Jacob Lockhart Clarke, FRS. Mult Scler (2011) 0.94
Characterization of tendon cell cultures of the human rotator cuff. Eur Cell Mater (2010) 0.94
MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study. Eur Radiol (2009) 0.94
Simvastatin locally applied from a biodegradable coating of osteosynthetic implants improves fracture healing comparable to BMP-2 application. Bone (2009) 0.94
Comparative safety study of three inactivated BTV-8 vaccines in sheep and cattle under field conditions. Vaccine (2009) 0.93
Myasthenia gravis in a patient with chronic active hepatitis C during interferon-alpha treatment. J Neurol Neurosurg Psychiatry (1996) 0.93
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult Scler (2012) 0.92
Effect of mechanical stimulation on osteoblast- and osteoclast-like cells in vitro. Cells Tissues Organs (2008) 0.92
Interaction of hepatitis A virus (HAV) precursor proteins 3AB and 3ABC with the 5' and 3' termini of the HAV RNA. Virus Res (1997) 0.92
Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy. Neurology (2001) 0.92
Vigilin contains a functional nuclear localisation sequence and is present in both the cytoplasm and the nucleus. FEBS Lett (1996) 0.92
Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patients. Neurology (1999) 0.91
Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis. Neurology (2010) 0.91
Low vitamin B12 levels and gastric parietal cell antibodies in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol (2012) 0.91
Microsurgical anterior approach to cervical discs. Review of 60 consecutive cases of discectomy without fusion. Acta Neurochir (Wien) (1984) 0.90
Fractures of the proximal humeral epiphysis. Orthop Clin North Am (1975) 0.90
Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry (2000) 0.90
Qualitative and quantitative evidence of anti-glutamic acid decarboxylase-specific intrathecal antibody synthesis in patients with stiff person syndrome. J Neuroimmunol (2010) 0.90
The long-term clinical outcome after pelvic ring injuries. Bone Joint J (2013) 0.90
The effect of zoledronic acid incorporated in a poly(D,L-lactide) implant coating on osteoblasts in vitro. J Biomed Mater Res A (2007) 0.90
Increased numbers of CCR5+ interferon-gamma- and tumor necrosis factor-alpha-secreting T lymphocytes in multiple sclerosis patients. Ann Neurol (2000) 0.89
Tularaemia seroprevalence of captured and wild animals in Germany: the fox (Vulpes vulpes) as a biological indicator. Epidemiol Infect (2012) 0.89
Long-term effect of rituximab in anti-mag polyneuropathy. Neurology (2008) 0.89
[The importance of a fast intrathecal lumbar infusion test not causing discomfort, for the diagnosis of hydrocephalus male resorptivus and for indication of shunt operation ]. Neurochirurgia (Stuttg) (1982) 0.89
[Extrapyramidal symptoms in meningiomas]. Schweiz Arch Neurol Neurochir Psychiatr (1975) 0.88